Table 1 Baseline Characteristics of Patients with stage IIIA pN2 status NSCLC
Baseline Characteristics of Patients in OS analysis | Baseline Characteristics of Patients in LCSS analysis | |||||
|---|---|---|---|---|---|---|
No.(%) of Patients (n = 3377) | No.(%) of Patients (n = 3077) | |||||
Demographic | No Port (n = 2179) | Port (n = 1198) | P Value for χ2 | No Port (n = 1983) | Port (n = 1094) | P Value for χ2 |
Age at diagnosis, years | ||||||
< 65 | 887 (40.7%) | 619 (51.7%) | <0.001 | 829(41.8%) | 573(52.4%) | <0.001 |
≥ 65 | 1292 (59.3%) | 579 (48.3%) | 1154(58.2%) | 521(47.6%) | ||
Sex | ||||||
Male | 1108 (50.4%) | 605 (50.5%) | 0.846 | 996(50.2%) | 539(49.3%) | 0.611 |
Female | 1071 (49.6%) | 593 (49.5%) | 987(49.8%) | 555(50.7%) | ||
Race | ||||||
White | 1789 (82.1%) | 967 (80.7%) | 0.564 | 1624(81.9%) | 882(80.6%) | 0.622 |
Black | 209 (9.6%) | 120 (10.0%) | 193(9.7%) | 110(10.1%) | ||
Other | 181 (8.3%) | 111 (9.3%) | 166(8.4%) | 102(9.3%) | ||
Location | ||||||
Main bronchus | 28 (1.3%) | 14 (1.2%) | 0.106 | 27(1.4%) | 11(1.0%) | 0.186 |
Upper lobe | 1221 (56.0%) | 728 (60.8%) | 1116(56.3%) | 663(60.6%) | ||
Middle lobe | 102 (4.7%) | 56 (4.7%) | 93(4.7%) | 52(4.8%) | ||
Lower lobe | 760 (34.9%) | 366 (30.5%) | 683(34.4%) | 336(30.7%) | ||
Overlapping/lung, NOS | 68 (3.1%) | 34 (2.8%) | 64(3.2%) | 32(2.9%) | ||
Tumor size, cm | ||||||
≤ 3.0 | 939 (43.1%) | 507 (42.3%) | 0.805 | 849(42.8%) | 464(42.4%) | 0.73 |
3.1 to 5.0 | 711 (32.6%) | 402 (33.6%) | 645(32.5%) | 370(33.8%) | ||
5.1 to 7.0 | 323 (14.8%) | 168 (14.0%) | 301(15.2%) | 153(14.0%) | ||
≥ 7.1 | 161 (7.4%) | 99 (8.3%) | 144(7.3%) | 87(8.0%) | ||
Unknown | 45 (2.1%) | 22 (1.8%) | 44(2.2%) | 20(1.8%) | ||
T stage | ||||||
T1 | 611 (28.0%) | 326 (27.2%) | 0.155 | 550(27.7%) | 299(27.3%) | 0.355 |
T2 | 1305 (59.9%) | 701 (58.5%) | 1181(59.6%) | 638(58.3%) | ||
T3 | 244 (11.2%) | 164 (13.7%) | 233(11.7%) | 150(13.7%) | ||
TX | 19 (0.9%) | 7 (0.6%) | 19(1.0%) | 7(0.7%) | ||
Laterality | ||||||
Right | 1206 (55.3%) | 687 (57.4%) | 0.241 | 1101(55.5%) | 640(58.6%) | 0.098 |
Left | 973 (44.7%) | 509 (42.6%) | 882(44.5%) | 452(41.4%) | ||
Unspecified | / | 2 | / | 2 | ||
Histology | ||||||
Non-small cell carcinoma | 141 (6.5%) | 81 (6.8%) | 0.113 | 128(6.5%) | 71(6.5%) | 0.076 |
Adenocarcinoma, NOS | 1366 (62.7%) | 795 (66.4%) | 1251(63.1%) | 738(67.4%) | ||
Squamous cell carcinoma, NOS | 609 (27.9&) | 294 (24.5%) | 546(27.5%) | 259(23.7%) | ||
Large cell carcinoma, NOS | 63 (2.9%) | 28 (2.3%) | 58(2.9%) | 26(2.4%) | ||
Surgery type | ||||||
Lobectomy | 1894 (86.9%) | 1087 (90.7%) | 0.001 | 1719(86.7%) | 999(91.3%) | <0.001 |
Pneumonectomy | 285 (13.1%) | 111 (9.3%) | 264(13.3%) | 95(8.7%) | ||
Number of positive lymph nodes | ||||||
1 | 655 (30.1%) | 286(23.9%) | <0.001 | 588(29.7%) | 263(24.1%) | 0.009 |
2 | 426 (19.6%) | 212(17.7%) | 386(19.5%) | 194(17.7%) | ||
3 | 278 (12.8%) | 173(14.4%) | 253(12.8%) | 156(14.3%) | ||
4 | 198 (9.1%) | 116(9.7%) | 183(9.2%) | 103(9.4%) | ||
5 | 135 (6.2%) | 103(8.6%) | 124(6.3%) | 96(8.8%) | ||
6 | 101 (4.6%) | 59(4.9%) | 92(4.6%) | 54(4.9%) | ||
7 | 62(2.8%) | 41(3.4%) | 56(2.8%) | 35(3.2%) | ||
≥ 8 | 200(9.2%) | 138(11.5%) | 187(9.4%) | 127(11.6%) | ||
No. of unspecified | 124(5.9%) | 70(5.9%) | 114(5.7%) | 66(6.0%) | ||
Number of positive lymph nodes | ||||||
≤ 3 | 1359 (66.1%) | 671 (59.5%) | <0.001 | 1227 (65.7%) | 613 (59.6%) | 0.001 |
> 3 (Unspecified Excluded) | 696 (33.9%) | 457 (40.5%) | 642 (34.3%) | 415 (40.4%) | ||